Hanxu Guo

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

NUF2 activated by YY1 promotes prostate cancer malignancy via p38/MAPK signaling axis and serves as a therapeutic target.

NUF2 activated by YY1 promotes prostate cancer malignancy via p38/MAPK signaling axis and serves as a therapeutic target.

Journal: Biochemical pharmacology

Published: December 09, 2024

De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review.

De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review.

Journal: Chinese medical journal

Published: April 08, 2024

Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study.

Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study.

Journal: European urology oncology

Published: October 29, 2023

Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.

Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.

Journal: Cancer research communications

Published: July 02, 2023

Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review.

Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review.

Journal: Frontiers in oncology

Published: December 08, 2022

Identification of a combined lncRNA prognostic signature and knockdown of lncRNA MANCR to inhibit progression of clear cell renal cell carcinoma by bioinformatics analysis.

Identification of a combined lncRNA prognostic signature and knockdown of lncRNA MANCR to inhibit progression of clear cell renal cell carcinoma by bioinformatics analysis.

Journal: Translational andrology and urology

Published: July 05, 2022

Identification of crucial genes and pathways associated with prostate cancer in multiple databases.

Identification of crucial genes and pathways associated with prostate cancer in multiple databases.

Journal: The Journal of international medical research

Published: June 04, 2021

The diagnostic and prognostic value of miR-92a in gastric cancer: A systematic review and meta-analysis.

The diagnostic and prognostic value of miR-92a in gastric cancer: A systematic review and meta-analysis.

Journal: Open medicine (Warsaw, Poland)

Published: March 06, 2021

Based on biomedical index data: Risk prediction model for prostate cancer.

Based on biomedical index data: Risk prediction model for prostate cancer.

Journal: Medicine

Published: August 13, 2020

Showing 1-9 of 9

Last Updated: 09/26/2026